These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 31102882)

  • 21. Interim buprenorphine treatment in opiate dependence: A pilot effectiveness study.
    Abrahamsson T; Widinghoff C; Lilliebladh A; Gedeon C; Nilvall K; Hakansson A
    Subst Abus; 2016; 37(1):104-9. PubMed ID: 26176490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Exp Clin Psychopharmacol; 2015 Dec; 23(6):428-35. PubMed ID: 26302337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Inpatient Medication-Assisted Therapy on Against-Medical-Advice Discharge and Readmission Rates.
    Wang SJ; Wade E; Towle J; Hachey T; Rioux J; Samuels O; Bonner C; Kirkpatrick C; O'Loughlin S; Foster K
    Am J Med; 2020 Nov; 133(11):1343-1349. PubMed ID: 32445720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pilot study about the feasibility and cost-effectiveness of electronic compliance monitoring in substitution treatment with buprenorphine-naloxone combination.
    Tacke U; Uosukainen H; Kananen M; Kontra K; Pentikänen H
    J Opioid Manag; 2009; 5(6):321-9. PubMed ID: 20073406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Group medication management for buprenorphine/naloxone in opioid-dependent veterans.
    Berger R; Pulido C; Lacro J; Groban S; Robinson S
    J Addict Med; 2014; 8(6):415-20. PubMed ID: 25275875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial.
    Wang X; Jiang H; Zhao M; Li J; Gray F; Sheng L; Li Y; Li X; Ling W; Li W; Hao W
    Asia Pac Psychiatry; 2019 Mar; 11(1):e12344. PubMed ID: 30460781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012-2017.
    Luu H; Slavova S; Freeman PR; Lofwall M; Browning S; Slade E; Bush H
    Drug Alcohol Depend; 2019 Dec; 205():107606. PubMed ID: 31606590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Primary Care Response to COVID-19 for Patients with an Opioid Use Disorder.
    Wilson CG; Ramage M; Fagan EB
    J Rural Health; 2021 Jan; 37(1):169-171. PubMed ID: 32277732
    [No Abstract]   [Full Text] [Related]  

  • 29. The Shelby Clinic Medication-Assisted Treatment for Opioid Addiction.
    Penn CL
    J Ark Med Soc; 2016 Aug; 113(2):30-32. PubMed ID: 30047628
    [No Abstract]   [Full Text] [Related]  

  • 30. Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.
    McDermott KA; Griffin ML; Connery HS; Hilario EY; Fiellin DA; Fitzmaurice GM; Weiss RD
    J Clin Psychiatry; 2015 Feb; 76(2):189-94. PubMed ID: 25562462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal association between pain severity and subsequent opioid use in prescription opioid dependent patients with chronic pain.
    Griffin ML; McDermott KA; McHugh RK; Fitzmaurice GM; Jamison RN; Weiss RD
    Drug Alcohol Depend; 2016 Jun; 163():216-21. PubMed ID: 27161860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: Retrospective study.
    Mamakwa S; Kahan M; Kanate D; Kirlew M; Folk D; Cirone S; Rea S; Parsons P; Edwards C; Gordon J; Main F; Kelly L
    Can Fam Physician; 2017 Feb; 63(2):137-145. PubMed ID: 28209683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.
    Ling W; Hillhouse MP; Saxon AJ; Mooney LJ; Thomas CM; Ang A; Matthews AG; Hasson A; Annon J; Sparenborg S; Liu DS; McCormack J; Church S; Swafford W; Drexler K; Schuman C; Ross S; Wiest K; Korthuis PT; Lawson W; Brigham GS; Knox PC; Dawes M; Rotrosen J
    Addiction; 2016 Aug; 111(8):1416-27. PubMed ID: 26948856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
    Bishop B; Gilmour J; Deering D
    Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence of validity and reliability of the Opiate Dosage Adequacy Scale (ODAS) in a sample of heroin addicted patients in buprenorphine/naloxone maintenance treatment.
    González-Saiz F; Lozano Rojas O; Trujols J; Alcaraz S; Siñol N; Pérez de Los Cobos J;
    Drug Alcohol Depend; 2018 Feb; 183():127-133. PubMed ID: 29247974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment.
    Barbosa-Leiker C; McPherson S; Layton ME; Burduli E; Roll JM; Ling W
    Am J Drug Alcohol Abuse; 2018; 44(4):488-496. PubMed ID: 29672167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of buprenorphine/naloxone maintenance treatment on sexual dysfunction, sleep and weight in opioid use disorder patients.
    Baykara S; Alban K
    Psychiatry Res; 2019 Feb; 272():450-453. PubMed ID: 30611963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers.
    Butler SF; Black RA; Severtson SG; Dart RC; Green JL
    J Subst Abuse Treat; 2018 Jan; 84():42-49. PubMed ID: 29195592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Group-based treatment of opioid use disorder with buprenorphine: A systematic review.
    Sokol R; LaVertu AE; Morrill D; Albanese C; Schuman-Olivier Z
    J Subst Abuse Treat; 2018 Jan; 84():78-87. PubMed ID: 29195596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.
    Murphy SM; McCollister KE; Leff JA; Yang X; Jeng PJ; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
    Ann Intern Med; 2019 Jan; 170(2):90-98. PubMed ID: 30557443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.